News
04-20-2016, 06:01 AM
Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age. This is among the findings of a new study from the Peter Munk Cardiac Centre, the Institute for Clinical Evaluative Sciences (ICES) and the Ted Rogers Centre for Heart Research, University Health Network.
More... (http://www.news-medical.net/news/20160420/Herceptin-drugs-for-breast-cancerc2a0linked-with-increased-risk-of-congestive-heart-failure.aspx)
More... (http://www.news-medical.net/news/20160420/Herceptin-drugs-for-breast-cancerc2a0linked-with-increased-risk-of-congestive-heart-failure.aspx)